Quantitative assessment of lncRNA H19 polymorphisms and cancer risk: a meta-analysis based on 48,166 subjects
Source abstract
Abstract
Recently, numerous studies have been performed to detect the association between H19 polymorphisms and cancer susceptibility. However, their results were inconsistent and controversial. So, we carried out a meta-analysis aiming to define the association exactly. Eligible studies were collected using PubMed and Embase databases up to March 31, 2019. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of association. Sensitivity analysis and publication bias were established to evaluate the robustness of our results. Totally, 60 studies involving 20763 cases and 27403 patients were analysed in our meta-analysis. Our results indicated that H19 rs217727 C > T polymorphism was significantly associated with increased cancer risk. In subgroup analysis, similarly increased risk could be found in gastrointestinal group for rs2839698 and protective effect was observed in rs2107425 polymorphism for cancer development in Caucasian population. Trial sequential analysis strengthened findings of our meta-analysis that cumulative evidence was adequate. In summary, our meta-analysis supported that H19 polymorphisms may be associated with cancer susceptibility.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer-related molecular mechanisms research · RNA modifications and cancer · Cholangiocarcinoma and Gallbladder Cancer Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurology, First Affiliated Hospital of China Medical University
Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, China Medical University
Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University
Funding
National Natural Science Foundation of China · Basis Research Foundation of Institutions of Higher Education of Liaoning Province of China
References (52)
Show source-provided references
1. 10.3322/caac.2155110.3322/caac.21551 ↗
2. 10.7150/ijbs.2163510.7150/ijbs.21635 ↗
3. 10.1007/s40471-019-0183-210.1007/s40471-019-0183-2 ↗
4. 10.3322/caac.2126210.3322/caac.21262 ↗
5. 10.1097/GRF.000000000000023910.1097/GRF.0000000000000239 ↗
6. 10.3322/caac.2144010.3322/caac.21440 ↗
7. 10.3322/caac.2133810.3322/caac.21338 ↗
8. 10.18632/oncotarget.783710.18632/oncotarget.7837 ↗
9. 10.1016/bs.acr.2017.06.00410.1016/bs.acr.2017.06.004 ↗
10. 10.1371/journal.pone.006412210.1371/journal.pone.0064122 ↗
11. 10.1002/bies.20090017010.1002/bies.200900170 ↗
12. 10.1128/mcb.10.1.28-36.199010.1128/mcb.10.1.28-36.1990 ↗
13. Gan L, Lv L, Liao S. Long noncoding RNA H19 regulates cell growth and metastasis via the miR223p/Snail1 axis in gastric cancer. Int J Oncol. 2019;54(6):2157–2168.
14. 10.1016/j.canlet.2013.01.03310.1016/j.canlet.2013.01.033 ↗
15. 10.1007/s13277-014-2185-510.1007/s13277-014-2185-5 ↗
16. 10.3390/ijms1811231910.3390/ijms18112319 ↗
17. 10.1016/j.cancergen.2017.06.00310.1016/j.cancergen.2017.06.003 ↗
18. 10.1186/s12943-015-0458-210.1186/s12943-015-0458-2 ↗
19. 10.1016/j.gene.2019.03.03610.1016/j.gene.2019.03.036 ↗
20. 10.1093/mutage/gew01810.1093/mutage/gew018 ↗
21. 10.18632/oncotarget.384010.18632/oncotarget.3840 ↗
22. 10.18632/oncotarget.2367310.18632/oncotarget.23673 ↗
23. 10.1371/journal.pmed.100009710.1371/journal.pmed.1000097 ↗
24. 10.1136/bmjopen-2016-01189010.1136/bmjopen-2016-011890 ↗
25. 10.1002/jcla.2282610.1002/jcla.22826 ↗
26. 10.1016/j.mgene.2017.07.00410.1016/j.mgene.2017.07.004 ↗
27. 10.1016/j.eururo.2008.01.06010.1016/j.eururo.2008.01.060 ↗
28. 10.1186/s12885-018-4795-610.1186/s12885-018-4795-6 ↗
29. 10.1186/s12881-018-0573-110.1186/s12881-018-0573-1 ↗
30. 10.1007/s10549-018-4814-y10.1007/s10549-018-4814-y ↗
31. 10.2147/OTT.S12796210.2147/OTT.S127962 ↗
32. 10.1186/s12957-017-1218-010.1186/s12957-017-1218-0 ↗
33. He TD, Xu D, Sui T, et al. Association between H19 polymorphisms and osteosarcoma risk. Eur Rev Med Pharmacol Sci. 2017;21(17):3775–3780.
34. Guo QY, Wang H, Wang Y. LncRNA H19 polymorphisms associated with the risk of OSCC in Chinese population. Eur Rev Med Pharmacol Sci. 2017;21(17):3770–3774.
35. 10.1097/MD.000000000000277110.1097/MD.0000000000002771 ↗
36. 10.18632/oncotarget.833010.18632/oncotarget.8330 ↗
37. 10.18632/oncotarget.1229910.18632/oncotarget.12299 ↗
38. 10.1042/BSR2018158210.1042/BSR20181582 ↗
39. Li Z, Niu Y. Association between lncRNA H19 (rs217727, rs2735971 and rs3024270) polymorphisms and the risk of bladder cancer in Chinese population. Minerva Urol Nefrol. 2019;71(2):161–167.
40. 10.1042/BSR2017165210.1042/BSR20171652 ↗
41. 10.1007/s13277-015-4497-510.1007/s13277-015-4497-5 ↗
42. 10.1186/1756-0500-5-41410.1186/1756-0500-5-414 ↗
43. 10.1093/carcin/bgq12810.1093/carcin/bgq128 ↗
44. 10.1093/hmg/ddp13810.1093/hmg/ddp138 ↗
45. 10.1371/journal.pone.000598310.1371/journal.pone.0005983 ↗
46. 10.1158/1055-9965.EPI-08-030010.1158/1055-9965.EPI-08-0300 ↗
47. 10.3322/caac.2138710.3322/caac.21387 ↗
48. 10.1007/978-981-10-5203-3_110.1007/978-981-10-5203-3_1 ↗
49. 10.18632/oncotarget.1253010.18632/oncotarget.12530 ↗
50. 10.18632/oncotarget.497610.18632/oncotarget.4976 ↗
51. 10.1016/j.molcel.2013.08.02710.1016/j.molcel.2013.08.027 ↗
52. 10.1016/j.mrrev.2016.10.00210.1016/j.mrrev.2016.10.002 ↗